This is consistent with the MSKCC cohort study findings, where BAP1 mutations were associated with poor prognostic factors, such as a higher T stage, higher nuclear grade, larger tumor size, more necrosis, and the presence of metastatic disease at presentation [23]. This evidence concerns the gene BAP1 and metastatic neoplasm.